KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

West Pharmaceutical Services (WST) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $979.0 million.

  • West Pharmaceutical Services' Total Non-Current Liabilities rose 1434.24% to $979.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $979.0 million, marking a year-over-year increase of 1434.24%. This contributed to the annual value of $898.9 million for FY2024, which is 100.0% up from last year.
  • Latest data reveals that West Pharmaceutical Services reported Total Non-Current Liabilities of $979.0 million as of Q3 2025, which was up 1434.24% from $953.3 million recorded in Q2 2025.
  • In the past 5 years, West Pharmaceutical Services' Total Non-Current Liabilities ranged from a high of $979.0 million in Q3 2025 and a low of $812.1 million during Q3 2022
  • Moreover, its 5-year median value for Total Non-Current Liabilities was $882.4 million (2021), whereas its average is $888.6 million.
  • Per our database at Business Quant, West Pharmaceutical Services' Total Non-Current Liabilities skyrocketed by 2318.86% in 2021 and then tumbled by 1100.27% in 2022.
  • Quarter analysis of 5 years shows West Pharmaceutical Services' Total Non-Current Liabilities stood at $940.2 million in 2021, then fell by 6.37% to $880.3 million in 2022, then grew by 1.1% to $890.0 million in 2023, then rose by 1.0% to $898.9 million in 2024, then increased by 8.91% to $979.0 million in 2025.
  • Its last three reported values are $979.0 million in Q3 2025, $953.3 million for Q2 2025, and $869.4 million during Q1 2025.